Bio Blast Pharma, a clinical-stage biotech developing treatments for rare and ultra-rare genetic diseases, filed on Friday with the SEC to raise up to $35 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2012, plans to list on the NASDAQ but has yet to announce a ticker. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
